CoChat

Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade is an active immunotherapeutic strategy that is currently in clinical trials in cancer. There are several ongoing trials of anti-CTLA-4 in the metastatic setting of prostate cancer patients with reported clinical responses consisting of decreases in the prostate specific antigen (PSA) tumor marker for some patients. Immunologic markers that correlate with these clinical responses are necessary to guide further development of anti-CTLA-4 therapy in the treatment of cancer patients. We recently reported that CD4(+) inducible co-stimulator (ICOS)(hi) T cells that produce interferon-gamma (IFN-gamma) are increased in the peripheral blood and tumor tissues of bladder cancer patients treated with anti-CTLA-4 antibody. Here we present data from the same clinical trial in bladder cancer patients demonstrating a higher frequency of CD4(+)ICOS(hi) T cells and IFN-gamma mRNA levels in nonmalignant prostate tissues and incidental prostate tumor tissues removed at the time of radical cystoprostatectomy. Our data suggest immunologic markers that can be used to monitor prostate cancer patients who receive anti-CTLA-4 therapy and indicate that the immunologic impact of anti-CTLA-4 antibody can occur in both tumor and nonmalignant tissues. These data should be taken into consideration for evaluation of efficacy as well as immune-related adverse events associated with anti-CTLA-4 therapy.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.0813175106

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

See all 221

Metadata

Authors
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., & Sharma, P.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Urology,
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Sharma, Padmanee
Venue
Proceedings of the National Academy of Sciences
Published
2009-02-24
Volume
106
Issue
8
Pages
2729-2734
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2155101465
Cited by
218
References
37
Citations by year
2026: 3 · 2025: 14 · 2024: 16 · 2023: 8 · 2022: 12 · 2021: 23 · 2020: 12 · 2019: 12 · 2018: 19 · 2017: 15 · 2016: 16 · 2015: 10 · 2014: 6 · 2013: 13 · 2012: 14
FWCI
6.49
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cancer Research Institute
  • Prostate Cancer Foundation
  • Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CTLA-4 blockade, CD4+ T cells, ICOS, interferon-gamma, prostate cancer, bladder cancer, tumor-infiltrating lymphocytes, immunological markers, immune-related adverse events, radical cystoprostatectomy
MeSH terms
Antibodies, Humans, Interferon-gamma, Male, Prostate, Prostatic Neoplasms, RNA, Messenger, CD4-Positive T-Lymphocytes, Antigens, CD, Lymphocytes, Tumor-Infiltrating, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. https://app.cochat.ai/papers/10.1073/pnas.0813175106
The paper
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., & Sharma, P. (2009). Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0813175106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.